Xyrem narcolepsy treatment maker Jazz Pharmaceuticals is growing both organically and through acquisitions, reports Investor’s Business Daily.
The company lost money for a number of years but turned a profit of $1.55 a share in 2010. Earnings have surged to $6.31 a share last year. Sales swelled to $872.4 million last year from $173.8 three years before that.
Jazz’s results have been boosted by its merger with Azur Pharma in 2012.
